Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 15/20 | 0.38 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4241244 | 1.00 | LMNA (0.41) | LMNATSHRHTTNPSR1HPGD | |
| SCHEMBL4241804 | 0.99 | LMNA (0.43) | LMNATSHRHTTNPSR1HPGD | |
| SCHEMBL4241802 | 0.99 | LMNA (0.43) | LMNATSHRHTTNPSR1HPGD | |
| SCHEMBL4245447 | 0.97 | LMNA (0.38) | LMNATSHRHTTNPSR1HPGD | |
| SCHEMBL4245450 | 0.97 | LMNA (0.38) | LMNATSHRHTTNPSR1HPGD | |
| SCHEMBL4237556 | 0.91 | LMNA (0.43) | LMNATSHRHTTNPSR1HPGD | |
| SCHEMBL4237559 | 0.91 | LMNA (0.43) | LMNATSHRHTTNPSR1HPGD | |
| SCHEMBL4241293 | 0.89 | GABRG2 (0.39) | CISD1CDK9ENPP2 | |
| SCHEMBL4241298 | 0.89 | GABRG2 (0.39) | CISD1CDK9ENPP2 | |
| SCHEMBL4240336 | 0.88 | LMNA (0.39) | LMNATSHRHTTNPSR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | claimed |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | disclosed |
| EP-1993536-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070249599-A1 | Novel Chemical Compounds | DUFFY KEVIN J | 2007-10-25 | — | — | US | disclosed |
| WO-2007103755-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249599-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | LMNA 1240/4885TSHR 4520/4885HTT 216/4885 |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | LMNA 4788/4885TSHR 1457/4885HTT 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.